AKT1 and central nervous system cancer: Over the past decade, many drugs have entered clinical trials for treatment of gliomas including epidermal growth factor receptor (EGFR) targeted therapies (Rajaratnam et al. 2020), protein kinase B (Akt) inhibitors (Kaley et al. 2019; Wen et al. 2013), mutant isocitrate dehydrogenase (IDH1) inhibitors (Fan et al. 2020) and calcium channel inhibitors (Holdhoff et al. 2017).